AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that an abstract with new Alzstatin data has been accepted for a poster presentation at the 2nd Swedish Meeting for Alzheimer Research which is held on April 21, 2022, at the Karolinska Institutet in Stockholm.
The abstract, titled Development of novel gamma-secretase modulators for the treatment of Alzheimer’s disease, will be presented by Dr. Maria Backlund at the 2nd Swedish Meeting for Alzheimer Research, hosted by the Center for Alzheimer Research at the Karolinska Institutet. Other authors include Dr. Märta Dahlström, Veronica Lidell och Dr. Pontus Forsell, Head of Research and Discovery på AlzeCure.
Data from the study shows that AC-0027875, a new potent small-molecule γ-secretase modulator (GSM) and part of AlzeCure’s research platform Alzstatin, has a very good pharmacokinetic profile and efficiently crosses the blood-brain barrier and reaches high concentrations in the brain. This, combined with the compound’s potent effect on γ-secretase, leads to AC-0027875 being able to reduce the amount of harmful Aβ42 by more than 50 percent. GSM’s represent a promising class of Aβ42-lowering anti-amyloidogenic substances for the treatment of Alzheimer's disease, and exhibits several key properties that make them suitable as a disease-modifying or preventive treatment for presymptomatic Alzheimer's disease.
“Our data show that AC-0027875 quickly reaches the brain at relevant concentrations and greatly reduces the amount of harmful Aβ42. In summary, our data suggest that γ-secretase modulators such as AC-0027875 represent a very promising anti-amyloidogenic therapy for the treatment of early Alzheimer's disease,” says Maria Backlund, ADME specialist at AlzeCure.
"Alzstatin is a small-molecule disease-modifying treatment for Alzheimer's that affects the production of the primary building block, Aβ42, of the amyloid plaques, which are so characteristic of the disease. The mechanism is particularly well suited for early, preventive treatment and these promising data show the potent effects that our compounds have," says Martin Jönsson, CEO of AlzeCure Pharma.
The abstract and the poster will be available on AlzeCure’s website after the presentation (https://www.alzecurepharma.se/en/publications).
